Further analysis focusing on BRAF class 1 as well as KRAS p.G12C, p.G12D, and p.G12V and the seven most common potentially druggable alterations revealed that both PTEN, AKT1, and AKT2 alterations were enriched in BRAF class 1 mutated samples, whereas alteration frequencies of EGFR, ERBB2, and FGFR1 were low in all four subgroups in comparison to RAS/BRAF‐wt samples in colon and rectal cancer (Fig. 4C,D). The gene discussed is BRAF; the disease is rectal cancer.